Endometriosis is a chronic, inflammatory condition where tissue similar to the lining of the uterus is found outside of the womb. It affects around one in ten women of reproductive age, causing pain, infertility and gastrointestinal symptoms.

Women often report difficulty getting their pain and other symptoms under control, despite medication or even surgery.

Our research, published today, found one in ten Australian women with endometriosis reported using cannabis to manage their pain and other symptoms.

Read more: I have painful periods, could it be endometriosis?

What did our study find?

We surveyed 484 women with surgically diagnosed endometriosis about the self-management strategies they used.

Of the respondents, who were aged 18 to 45, 76% reported using self-management techniques in the past six months. This included the use of heat packs (70%), dietary changes (44%), exercise (42%), yoga or pilates (35%) and cannabis (13%).

Out of all of the self-management techniques, cannabis was rated as the most effective for managing pain.

Women who reported higher levels of pain were more likely to use cannabis than those with milder symptoms. This may be because they couldn’t get relief through other measures.

Respondents who used cannabis also reported improvements in other symptoms including gastrointestinal problems, nausea, anxiety, depression and sleep.

One in ten cannabis users reported side effects, which included anxiety, drowsiness and tachycardia (fast heart rate). This is consistent with other research.

How could cannabis help treat endometriosis symptoms?

The endocannabinoid system (ECS) is a complex regulatory system comprised of various receptors, chemicals that bind with these receptors, and enzymes. It helps maintain balance (homeostasis) in our bodies and is important for a wide range of actions, including metabolism, inflammation and immune function.

The ECS is distributed throughout most organs in the human body, but is more abundant in the central nervous, immune and female reproductive systems.

Chemicals from cannabis, including the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD), can interact with the ECS and other receptor types. This suggests a mechanism for how cannabis may alleviate pelvic pain in women with endometriosis.

Read more: Marijuana is a lot more than just THC - a pharmacologist looks at the untapped healing compounds

Emerging research shows medicinal cannabis can help manage a number of conditions, including chronic pain in adults, the spasticity of multiple sclerosis, intractable epilepsy (where seizures can’t be controlled with medication) and chemotherapy-induced nausea and vomiting.

Research is still in its infancy in women with pelvic pain, but one study found women with pelvic pain may benefit from using medicinal cannabis. It may also allow them to reduce their opioid pain-killer intake.

Is it legal?

Medical practitioners in Australia can legally prescribe medicinal cannabis through regulated pathways such as the Special Access Scheme Category B and the Authorised Prescriber Scheme. These pathways are typically used by doctors for unapproved medicines.

According to discussions with prescribing doctors and patients, approvals for medicinal cannabis for pain associated with endometriosis have been successful through these regulated, legal channels.

However, at the time our survey was administered, in late 2017, it’s likely most women who were using cannabis accessed it illicitly. No Special Access Scheme approvals had been granted for endometriosis at the time. Further, most women we surveyed reported smoking cannabis, which is very rarely prescribed by doctors in Australia.

Despite the perception that “natural” equals safe, cannabis use does come with risks. These should be discussed with and monitored by medical professionals.

Why do women resort to cannabis and self care?

Both surgical and pharmaceutical treatments are commonly used for endometriosis.

Surgery can reduce pain, at least in the short to medium term.

Recent reviews have found hormonal treatment options can be effective at managing pain but these are often discontinued or avoided due to significant side effects, such as headaches, mood swings and depression.

Non-steroidal anti-inflammatories (NSAIDs) like ibuprofen don’t seem to be effective at alleviating pain from endometriosis.

Read more: Endometriosis costs women and society $30,000 a year for every sufferer

In the US, opioids (oxycodone and codeine) are commonly prescribed for endometriosis. Rates of opioid prescription are much lower in Australia but it’s still relatively common among women. This puts women at risk of dependence and potential overdose.

Women with endometriosis report wide-ranging negative impacts on their daily lives, from having to reduce their social activities to problems going to work or studying. It can also cause poor mental and emotional health and affect their sexual and romantic relationships.

So what needs to happen next?

Our survey data shows Australian women are already using cannabis for endometriosis-associated pain, regardless of legality, and with few reported side effects.

However, these survey responses are self-reported so there may be issues such as recall bias. This can lead to over or underestimation of either benefits or harms.

Given women with endometriosis are often suffering without adequate pain control, well designed clinical trials are urgently needed to determine how effective and safe quality-controlled medicinal cannabis might be in treating the symptoms of endometriosis.

Read more: CBD: Rising star or popular fad?

Justin Sinclair sits on the scientific advisory board of United in Compassion (medicinal cannabis patient advocacy) pro bono. He receives funding from BioCeuticals to conduct his PhD research. The material in this article and the original research survey was not from any externally funded research.

Mike Armour is a clinical advisory board member for Endometriosis Australia and recieves funding from Spectrum Cannabis to explore views for using medicial cannabis in primary dysmenorrhea. The material in this article and the original research survey was not from any externally funded research.